Volume | 7,512 |
|
|||||
News | - | ||||||
Day High | 3.5999 | Low High |
|||||
Day Low | 3.433 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.55 | 3.433 | 3.5999 | 3.33 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
34 | 7,512 | $ 3.55 | $ 26,678 | - | 1.699 - 9.6799 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
11:24:41 | 380 | $ 3.433 | USD |
Marker Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
32M | 8.89M | - | 3.31M | -8.24M | -0.93 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Marker Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.80 | 4.0991 | 3.33 | 3.68 | 15,035 | -0.367 | -9.66% |
1 Month | 4.04 | 4.3799 | 3.33 | 3.91 | 10,030 | -0.607 | -15.02% |
3 Months | 4.49 | 4.93 | 3.33 | 4.33 | 15,187 | -1.06 | -23.54% |
6 Months | 2.87 | 6.1568 | 2.8016 | 4.59 | 48,855 | 0.563 | 19.62% |
1 Year | 1.70 | 9.6799 | 1.699 | 4.70 | 85,235 | 1.73 | 101.94% |
3 Years | 30.20 | 36.50 | 0.6706 | 8.08 | 486,114 | -26.77 | -88.63% |
5 Years | 54.60 | 91.70 | 0.6706 | 19.31 | 651,766 | -51.17 | -93.71% |
Marker Therapeutics Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |